Caitong International Asset Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Caitong International Asset Management’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$104	Buy	+39	New	+$96	﹤0.01%	2171

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Caitong International Asset Management's ABOS Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 39 shares worth $104. The stake represents ﹤0.01% of the portfolio and ranks #2171 among its holdings.

96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

Caitong International Asset Management held 39 shares of Acumen Pharmaceuticals worth $104 as of Q2 2026.
Acumen Pharmaceuticals was a new Caitong International Asset Management position in Q2 2026.
Acumen Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2171 holding.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.